Galecto (GLTO) Competitors $5.26 +0.63 (+13.69%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLTO vs. LSB, LGVN, NAII, DRRX, CDIO, ATHE, LVTX, GDTC, EQ, and ENLVShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Lakeshore Biopharma (LSB), Longeveron (LGVN), Natural Alternatives International (NAII), DURECT (DRRX), Cardio Diagnostics (CDIO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), CytoMed Therapeutics (GDTC), Equillium (EQ), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Lakeshore Biopharma Longeveron Natural Alternatives International DURECT Cardio Diagnostics Alterity Therapeutics LAVA Therapeutics CytoMed Therapeutics Equillium Enlivex Therapeutics Lakeshore Biopharma (NASDAQ:LSB) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Which has higher valuation & earnings, LSB or GLTO? Galecto has lower revenue, but higher earnings than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeshore Biopharma$80.82M0.31-$61.09MN/AN/AGalectoN/AN/A-$38.35M-$19.14-0.28 Does the MarketBeat Community prefer LSB or GLTO? Galecto received 32 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformLakeshore BiopharmaN/AN/AGalectoOutperform Votes3260.38% Underperform Votes2139.62% Which has more volatility & risk, LSB or GLTO? Lakeshore Biopharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Do institutionals and insiders hold more shares of LSB or GLTO? 52.6% of Lakeshore Biopharma shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 11.9% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor LSB or GLTO? In the previous week, Lakeshore Biopharma's average media sentiment score of 1.00 beat Galecto's score of 0.00 indicating that Lakeshore Biopharma is being referred to more favorably in the media. Company Overall Sentiment Lakeshore Biopharma Positive Galecto Neutral Do analysts recommend LSB or GLTO? Galecto has a consensus target price of $10.00, suggesting a potential upside of 89.97%. Given Galecto's stronger consensus rating and higher probable upside, analysts plainly believe Galecto is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LSB or GLTO more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets Lakeshore BiopharmaN/A N/A N/A Galecto N/A -76.96%-66.59% SummaryGalecto beats Lakeshore Biopharma on 7 of the 12 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.95M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.289.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / Book0.186.055.314.79Net Income-$38.35M$154.90M$122.54M$224.99M7 Day Performance10.36%1.35%1.44%2.37%1 Month Performance12.00%0.41%2.51%4.40%1 Year Performance-68.10%3.08%25.32%20.10% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.3533 of 5 stars$5.26+13.7%$10.00+90.0%-68.1%$6.95MN/A-0.2840High Trading VolumeLSBLakeshore Biopharma1.2606 of 5 stars$2.86-7.1%N/AN/A$26.62M$672.27M0.00773Upcoming EarningsPositive NewsGap UpLGVNLongeveron3.4804 of 5 stars$1.77-1.1%$8.67+389.6%-82.1%$26.26M$1.89M-0.2823Positive NewsNAIINatural Alternatives International1.7155 of 5 stars$4.20-0.2%N/A-33.2%$26.04M$112.98M-2.92290Analyst ForecastPositive NewsDRRXDURECT4.0314 of 5 stars$0.83+7.0%$5.00+506.1%+16.1%$25.61M$8.59M-1.3580CDIOCardio Diagnostics3.1518 of 5 stars$0.63-6.4%$2.00+218.5%-76.1%$25.40M$35,688.000.007Positive NewsATHEAlterity Therapeutics2.1682 of 5 stars$3.45+3.3%$6.00+73.9%+83.9%$25.20MN/A0.0010Short Interest ↑LVTXLAVA Therapeutics3.1165 of 5 stars$0.99+1.5%$3.33+236.7%-40.9%$25.10M$7.35M-0.9660Positive NewsGDTCCytoMed Therapeutics1.444 of 5 stars$2.26-18.1%$5.00+121.2%-39.0%$24.72MN/A0.00N/APositive NewsGap UpEQEquillium2.254 of 5 stars$0.70-0.8%$5.00+619.3%-22.3%$24.63M$45.91M-4.9640ENLVEnlivex Therapeutics3.6144 of 5 stars$1.15+0.4%$9.50+726.1%-58.8%$24.62MN/A-1.1770Positive News Related Companies and Tools Related Companies Lakeshore Biopharma Competitors Longeveron Competitors Natural Alternatives International Competitors DURECT Competitors Cardio Diagnostics Competitors Alterity Therapeutics Competitors LAVA Therapeutics Competitors CytoMed Therapeutics Competitors Equillium Competitors Enlivex Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLTO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
